Kornimate/medical-research-clean huggingface dataset:
acoart ⅰ / sfa china

Conditions: Peripheral Artery Disease

Summary: the purpose of this study is to determine whether deb is more effective than common pta balloon in long-term vessel patency and inhibiting restenosis.


Eligibility criteria:
inclusion criteria: * age between 18 and 80 years * patients with peripheral artery disease (pad), with rutherford classification between 2 and 5 * an occlusion or a minimum grade of stenosisprimary over 70% in the superficial femoral artery an /or the popliteal artery * total length of treat lesion(s)is less or equal to 40cm * signed patient informed consent form exclusion criteria: * plasma cr level greater than 150 umol/l in patients * patients with acute thrombosis requiring lysis or thrombectomy * patient with a lysis or an lower limb intervention as a therapy within the last 6 weeks * patient requiring intervention in both lower limbs at the same time * target lesion can't be cross by the guide wire * distal outflow through less than one lower leg vessel * known hypersensitivity to aspirin, heparin, clopidogrel,paclitaxel, contrast medium, etc. * patients participating in another clinical trials with interfere with this trial in the past 3 months * pregnancy and lactating woman * untreatable bleeding diatheses * other diseases, such as cancer, liver disease, or cardiac insufficiency, which may lead to protocol violations or markedly shorten a patients's life expectancy(less than 2 years) * patients unable or unwilling to participate this trial

Keywords: drug eluting balloon catheter
hemidiaphragmatic paralysis with diluted continuous interscalene plexus infusions

Conditions: Diaphragmatic Paralysis; Postoperative Pain; Acute Pain; Shoulder Pain; Shoulder Injury

Summary: interscalene brachial plexus block (isb) constitutes the analgesic criterion standard for shoulder surgery. however, it is associated with a high incidence of hemidiaphragmatic paralysis (hdp) that may not be tolerated by patients with chronic pulmonary disease. continuous isbs have not avoided this complication with the reported and regularly used local anesthetic dilutions (i.e. 0.125% bupivacaine, 0.25% ropivacaine, etc). this observational study will register the incidence of hdp in continuous interscalene block (cisb) using a very diluted solution of levobupivacaine (0.04%) in patients undergoing arthroscopic shoulder surgery. the main objective of this study is to determine the frequency of hdp the first postoperative day before patient discharge(pod).


Eligibility criteria:
inclusion criteria: * age between 18 and 80 years * american society of anesthesiologists classification 1-3 * body mass index between 20 and 35 exclusion criteria: * adults who are unable to give their own consent * pre-existing neuropathy (assessed by history and physical examination) * coagulopathy (assessed by history and physical examination and, if deemed clinically necessary, by blood work up i.e. platelets ≤ 100, international normalized ratio ≥ 1.4 or prothrombin time ≥ 50) * renal failure (assessed by history and physical examination and, if deemed clinically necessary, by blood work up i.e. creatinine ≥ 100) * hepatic failure (assessed by history and physical examination and, if deemed clinically necessary, by blood work up i.e. transaminases ≥ 100) * allergy to local anesthetics (las) * pregnancy * prior surgery in the ipsilateral neck region * chronic pain conditions

Keywords: hemidiaphragmatic paralysis continuous plexus block interscalene plexus block diluted local anesthetic infusion ambulatory regional analgesia ambulatory continuous nerve block continuous local anesthetic infusion
covid-19 pandemic and worldwide organ procurement

Conditions: COVID-19

Summary: end-stage organ failure is estimated to affect more than 4 to 6 million persons worldwide. in 2018, transplant systems across the globe enabled around 150,000 patients to benefit from a kidney, heart, lung, liver, or other solid organ, a number that was far less than the demand. according to data from the world health organization, more than 1,500,000 persons live with a transplanted organ worldwide. in the us, approximately 40,000 patients receive an organ transplant every year, but 120,000 still remain waitlisted for transplantation today, with 7,600 dying annually while waiting for an organ transplant. a similar lack of organs and high death rates on the waiting list affect patients in europe and many other countries. as nations adjust to new realities driven by the coronavirus (covid-19) outbreak, many health care providers, institutions and patients are concerned about the potential impact that covid-19 will have on organ donation and transplantation. one concern is that transplant recipients may have a greater susceptibility to infection and greater viral burden. a second concern is that hospitals will lack the resources in terms of staff and equipment to care for recipients after transplantation, who often require intensive care and multispecialty management. because of the overwhelming healthcare system burden, a dramatic negative effect on worldwide organ donation and transplantation is anticipated, but has not been measured. our objective was to quantify the worldwide impact of covid-19 pandemic on organ donation and transplantation and consequences for waitlisted patients.


Eligibility criteria:
inclusion criteria: * all organs procured for transplantation and transplanted during the observation period. these include kidney, lung, liver, heart, and combined transplantations. exclusion criteria: * none

Keywords: organ procurement transplantation pandemic
effect of care management on diabetes outcomes

Conditions: Diabetes Mellitus

Summary: the purpose of the study is to determine if a nurse managed, protocol driven, disease management process for diabetes results in improved attainment of therapeutic goals for diabetes compared to usual care. it is hypothesized that implementation of the disease management process will improve the percentage of diabetic individuals attaining all three therapeutic targets (hgba1c\<8.0%, ldl\<100mg/dl, and bp\<130/80mmhg) by 10% compared to usual care.


Eligibility criteria:
inclusion criteria: * enrolled at minneapolis vamc * type 1 or 2 diabetes * blood pressure at screening visit \> 140mmhg systolic or \> 90mmhg diastolic or hgba1c at screening visit \> 9.0% or ldl at screening visit \> 100mg/dl exclusion criteria: * primary care provider unwilling to have participant included in study * life expectancy \< 1 year * unable to give consent * severe mental health condition * pregnant or planning on becoming pregnant

Keywords: diabetes mellitus chronic care model case management
danish randomized trial of external ventricular drainage cessation in aneurysmal subarachnoid haemorrhage

Conditions: Aneurysmal Subarachnoid Hemorrhage; Hydrocephalus

Summary: the drain trial is an international multi-centre, 1:1 randomised, parallel-group, superiority clinical trial investigating gradual weaning vs. prompt closure of external ventricular drainage in patients with hydrocephalus following asah. the primary objective is to investigate the beneficial and harmful effects of gradual weaning versus prompt closure of evd treatment in patients with asah.


Eligibility criteria:
inclusion criteria * \>= 18 years of age * diagnosis of aneurysmal subarachnoid haemorrhage (asah) * external ventricular drain (evd) for \>= 6 days * drain output of =\< 220 ml on day of randomisation * drain resistance of 10 or 15 cm h2o * stable or improving glasgow coma scale (gcs) \>= 9 during the last 24 hours * signed informed consent (from patient or next-of-kin) exclusion criteria * none-tolerability of an increase of resistance to 10 cm h2o due to clinical deterioration or an increase in icp * severe pre-existing (physical or mental) disability or severe co-morbidity that would lead to poor outcome even if the patient made a full recovery from the asah * life expectancy shorter than 48 hours after admission

Keywords: external ventricular drain weaning closure controlled trial randomised trial outcome assessment blinded
glucose absorption and gut hormone secretion after gastric bypass

Conditions: Overweight

Summary: to investigate the impact of canagliflozin on secretion of gut hormones, in particular glucagon-like peptide 1 (glp-1) in gastric bypass operated patients.

glucose is a potent stimulus for glp-1 secretion after gastric bypass surgery and the sglt-1 transporter appears to be crucial for this response. the study will investigate the effects of sglt-1/sglt-2 inhibition (by canagliflozin) on secretion of glp-1 and other gut hormones after gastric bypass surgery.

Eligibility criteria:
inclusion criteria: •uncomplicated gastric bypass surgery performed minimum 12 months prior to study exclusion criteria: * type 1 or 2 diabetes mellitus prior to or after gastric bypass surgery * pregnancy or breastfeeding * haemoglobin levels below 6,5 mm

Keywords: glucagon-like peptide-1 glucose gastric bypass bariatric surgery obesity diabetes
low risk acute coronary syndrome

Conditions: Low Risk Acute Coronary Syndrome

Summary: a large number of patients are diagnosed with low risk acs, and these individuals are at significant cardiovascular risk. though guidelines recommend stress testing to manage low risk acs patients, evidence supporting this recommendation is not based on trials examining this population. a well-designed, randomized trial is warranted to determine if stress testing is useful in managing low risk acs. if medical therapy alone is equivalent as the investigators hypothesize, healthcare expenditures could be reduced and patients may not be exposed to the harms associated with more invasive cardiac testing such as coronary angiography.


Eligibility criteria:
inclusion criteria: 1. timi score \< or = to 2(12) 2. timi risk score of 3 with no known cad, greater than 50% in one or more vessels 3. normal cardiac biomarkers (3 sets over 12-88 hours) 4. no evidence of acute ischemia on electrocardiograms 5. normal ejection fraction (\>40%) on echocardiography 6. age 30-75 7. ability to complete noninvasive stress test 8. ability to provide informed consent exclusion criteria: 1. presence of another medical condition to explain chest pain or non-cardiac chest pain (i.e. pneumonia, costochondritis) 2. any patient who is initially classified as low risk but whom develops recurrent symptoms of ischemia, hemodynamic instability, or arrhythmias attributable to ischemia 3. evidence of ischemia on electrocardiogram 4. abnormal cardiac biomarkers 5. history of medical noncompliance or social circumstances preventing compliance 6. life span estimated at \<1 year 7. pregnancy 8. refusal to sign consent

Keywords: low risk acs, acute coronary syndrome, stress testing, non-stress testing
supervised exercise-based rehabilitation for people with intermittent claudication in denmark

Conditions: Intermittent Claudication

Summary: the goal of this project is to implement a protocol for a supervised exercise therapy intervention including smoking cessation in the municipalities in region zealand in denmark. the participants are adults with intermittent claudication. the objective of this project is to describe: 1. the development and design of the implementation process of a rehabilitative intervention including set and smoking cessation in region zealand with a 6-month follow-up period after completion of the set. 2. the ongoing quality monitoring process of the implementation in terms of referral, recruitment, retention, data completeness, intervention delivery and attendance and to collect feedback that will guide refinements of the intervention delivery and data collection. 3. outcomes available for assessment of benefits and harms from the set intervention. participants will be asked to do supervised exercise therapy by walking on a treadmill for 3 times a week for 12 weeks, and engage in smoking cessation, if they are smoking.


Eligibility criteria:
inclusion criteria: * relevant symptoms of intermittent claudication; leg pain when walking due to arteriosclerosis and relieve of symptoms during rest. * distal blood pressure with an ankle-brachial index (abi) \> 50 mmhg for non-diabetics or toe brachial index (tbi) \> 40 mmhg for diabetics. exclusion criteria: • evaluated by a vascular surgeon: patients with contraindications e.g. medical issues or comorbidity that enables a participation in set are not referred.

Keywords: exercise therapy smoking cessation implementation stakeholders walking treadmill
the incidence of metabolic syndrome among obese children in our region

Conditions: Metabolic Syndrome

Summary: the aim of this study is to determine the prevalence of metabolic syndrome amongst obese children in our region with a body mass index (bmi) above the 95th percentile for age and sex.


Eligibility criteria:
inclusion criteria: * children with bmi over 95 percentile exclusion criteria: * obesity secondary to medication use * obesity secondary to genetic disease
a study to evaluate ro7204239 in participants with facioscapulohumeral muscular dystrophy

Conditions: Facioscapulohumeral Muscular Dystrophy (FSHD)

Summary: the purpose of this study is to evaluate the pharmacodynamics, safety, tolerability, pharmacokinetics, and efficacy of ro7204239, a humanized monoclonal antibody that binds to human latent myostatin, in ambulant adult participants with facioscapulohumeral muscular dystrophy (fshd).


Eligibility criteria:
inclusion criteria: * genetic confirmation of fshd1 or fshd2 * clinical findings consistent with fshd * ability to walk unassisted * ricci clinical severity scale score ≥ 2.5 and ≤ 4 * agreement to maintain the same frequency and intensity of physiotherapy, occupational therapy, and other forms of exercise during the clinical study exclusion criteria: * pregnancy or breastfeeding, or intention of becoming pregnant during the study or within 17 months after the final dose of ro7204239 * current or previous treatment (or receipt) of anti-myostatin therapies * treatment with any investigational therapy within 90 days prior to screening, or 5 drug-elimination half-lives of the drug, whichever is longer * contraindications to mri scans * presence of clinically significant ecg abnormalities * presence of clinically significant cardiovascular disease * presence of clinically significant abnormal findings in echocardiography at screening, with the exception of mitral valve prolapse, which does not exclude participants from the study * any major illness within 1 month before screening * ascertained or presumptive hypersensitivity (e.g., anaphylactic reaction) to ro7204239, or to the constituents of its formulation * history of malignancy (except in situ basal cell carcinoma of the skin and in situ carcinoma of the cervix of the uterus that have been excised and resolved with documented clean margins on pathology) * any clinically relevant history of anaphylactic reaction requiring inotropic support * any abnormal skin conditions, pigmentation, or lesions in the area intended for sc injection (abdomen) and that would prevent visualization of potential injection-site reactions to ro7204239 * immobilization, surgical procedures, fracture, or trauma to the upper or lower limbs within 90 days prior to screening or longer, if judged by the investigator that it may affect motor function assessment * any planned surgery that may affect a participant's motor function assessment, including participants who have had surgery of scapular fixation within the 12 months preceding screening or that are planned during the study * use of the following medications within 90 days prior to enrollment: salbutamol or another β2-adrenergic agonist taken orally; creatine; recombinant human growth hormone; recombinant human insulin growth factor-1; testosterone, oxandrolone, or other anabolic steroid; chronic oral or parenteral use of corticosteroids (inhaled corticosteroid use is allowed) unless required to manage injection reactions;agents anticipated to increase or decrease muscle volume or strength
supervised exercise to promote infiltration of nk-cells into the tumor

Conditions: Breast Cancer

Summary: 'supervised exercise to promote infiltration of nk-cells into the tumor? the objective of this feasibility study is to 1) study trial feasibility in terms of patient enrollment and the percentage of tumor biopsies that can be examined successfully, and 2) generate preliminary data on the potential effects of exercise on immune function assessed in the tumor and in blood.

this is a multicenter randomized controlled feasibility trial, in which 20 women with breast cancer scheduled for neoadjuvant 2 or 3 weekly ac-t(h) chemotherapy will be randomized into a combined aerobic and resistance exercise intervention group or a usual care (no exercise) control group, during the first 6 weeks (2 or 3 cycles) of chemotherapy. patients from the control group will receive care as usual and are requested to maintain their usual daily physical activities. in order to limit contamination (increase of exercise in the control group), non-participation and prevent dropout, the control group will be offered the same 6-week exercise intervention after the tumor biopsy has been taken after 6 weeks.

Eligibility criteria:
inclusion criteria: * stage i-iii breast cancer * scheduled for neoadjuvant chemotherapy with 2 or 3-weekly adriamycin/cyclofosfamide, followed by paclitaxel weekly +/- trastuzumab * willing to undergo an additional ultrasound guided biopsy * ecog-performance score ≤ 2 (able to perform basic activities of daily living such as walking or biking) exclusion criteria: * addition of immuno- or targeted therapy at start of neoadjuvant chemotherapy * currently participating in structured vigorous aerobic exercise and/or resistance exercise (≥2 days per week). * cognitive disorder or severe emotional instability * presence of other disabling co-morbidity that might hamper physical exercise e.g. heart failure (nyha classes 3 and 4), chronic obstructive pulmonary disease (copd, gold 3 and 4), orthopaedic conditions and neurological disorders (e.g., hernia, paresis, amputation, active rheumatoid arthritis); * immunosuppressive medication (e.g. corticosteroids (other than used as part of standard chemotherapy premedication protocol), cyclosporine) * immunodeficiency (primary or secondary) * impossibility to perform an ultrasound-guided biopsy of the tumor

Keywords: stage i-iii breastcancer neoadjuvant chemotherapy exercise nk-cells
effects of latissimus dorsi stretching on functional disability related to chronic low back pain

Conditions: Mechanical Low Back Pain

Summary: the main objective of the study is to determine effects of latissimus dorsi stretching on functional disability related to chronic low back pain

a single-blinded,randomized clinical trial will be conducted in /multiple rehabilitation centers of rawalpindi and islamabad, after taking approval from erb/irb respective centers. the study duration will be 3 months. the study participants will be having mechanical low back pain. the intervention will be included latissmus dorsi stretching along with spinal stabilization exercises in one group and in comparative group spinal stabilization exercises alone. oswestry disability index (odi) will be used to measure the disability related to the chronic low back pain.

Eligibility criteria:
inclusion criteria: * male and female * 20 to 60 years * chronic mechanical low back pain exclusion criteria: * patients who had any type of injury or fracture which limits rehabilitation * patients with the symptoms of radiating pain * who had disc pathology and spinal cord injury * patients with medical conditions
effects of septorhinoplasty on allergic rhinitis

Conditions: Allergic Rhinitis

Summary: allergic rhinitis (ar) is a chronic inflammatory disease that affects almost 30% of adult population. some patients associate septal deviation, main cause of chronic nasal obstruction, and ar. current literature about ar treatment with septoplasty (stp) is still contradictory, because is thought that patients with ar are not able to appreciate improvement after surgery. patients diagnosed with allergic rinitis and septal deviation were evaluated to determined life quality and airflow obstruction evolution after stp.

this is a prospective quasi experimental study. after being informed about the study, patients that signed written informed consent were included in the study. in week 0 before surgery, all measurements and questionnaires were performed. 1 month after surgery, measurements were repeated. after screening, patient´s obstruction was evaluated by anterior rhinomanometry (rnma), and quality of life scored through esprint scale. esprint is a validated spanish questionnaire about daily life activity, sleep, psycology and perception of affection by allergic rhinitis. symtoms were evaluated with visual analogue scale (vas) and clinical history. symptoms like sneezing, itchy nose, ocular symptoms and/or nasal obstruction. also medication (intranasal corticosteroid, antileucotrienos, antihistamines eye drops , antishistamines) frequency use was registered.

Eligibility criteria:
inclusion criteria: * clinical diagnosis of allergic rhinitis * diagnosis of nasal obstruction with septal deviation exclusion criteria: * previous nasal surgery * smokers * chronic obstructive pulmonary disease * psychiatric disorders * malignant tumors * severe hepatopathy * obstructive sleep apnea

Keywords: septoplasty vas quality of life allergic rhinitis nasal obstruction
study of atrasentan in men with non-metastatic, hormone-refractory prostate cancer

Conditions: Prostatic Neoplasms

Summary: this study is being done to evaluate the safety and efficacy of atrasentan in men with non-metastatic hormone-refractory prostate cancer.


Eligibility criteria:
inclusion criteria: * have been diagnosed with prostate cancer. * have a rising psa while on hormone therapy or following surgical castration. exclusion criteria: * have evidence of distant metastatic disease on screening bone scan or ct scan. * have received cytotoxic chemotherapy. * have received opioid or narcotic medications (such as codeine or morphine) or radiation for pain caused by your prostate cancer in the last 6 months.

Keywords: hormone-refractory prostate cancer